part Part I Angiogenesis in Cancer -- chapter 1 Strategies to Profilong the Nonangiogenic Dormant State of Human Cancer -- chapter 2 Vascular Endothelial Growth Factor: Basic Biology and Clinical Implications -- chapter 3 Angiogenesis in Solid Tumors -- chapter 4 Pathophysiologic Role of VEGF in Hematologic Malignancies -- chapter 5 Tumor Microenvironment and Angiogenesis -- part Part II Targeting Angiogenesis for Cancer Therapy -- chapter 6 Tyrosine Kinase Inhibitors of Angiogenesis -- chapter 7 Development of Antiangiogenic Monoclonal Antibodies for Cancer Therapy -- chapter 8 Targeting Fibroblast Growth Factor=Fibroblast Growth Factor Receptor System in Angiogenesis -- chapter 9 Development of the VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and Discovery of the Next Generation of Angiogenesis Targets -- chapter 10 Proteinases and Their Inhibitors in Angiogenesis -- chapter 11 Prostaglandins and COX-2: Role in Antiangiogenic Therapy -- chapter 12 Integrins, Adhesion, and Coadhesion Inhibitors in Angiogenesis -- chapter 13 Conventional Therapeutics with Antiangiogenic Activity -- chapter 14 Vascular Disrupting Agents -- chapter 15 Vascular and Hematopoietic Stem Cells as Targets for Antiangiogenic Therapy -- chapter 16 Genetic Strategies for Targeting Angiogenesis -- chapter 17 Identification of New Targets Using Expression Profiles -- part Part III Translating Angiogenesis Inhibitors to the Clinic -- chapter 18 Clinical Trial Design and Regulatory Issues -- chapter 19 Surrogate Markers for Antiangiogenic Cancer Therapy -- chapter 20 Noninvasive Surrogates -- chapter 21 Pharmacodynamic Markers in Tissues -- chapter 22 Blood-Based Biomarkers for VEGF Inhibitors -- part Part IV Treatment of Specific Cancers with Angiogenesis Inhibitors -- chapter 23 Antiangiogenic Therapy for Colorectal Cancer -- chapter 24 Combined Modality Therapy of Rectal Cancer -- chapter 25 Antiangiogenic Therapy for Breast Cancer -- chapter 26 Antiangiogenic Therapy for Lung Malignancies -- chapter 27 Antiangiogenic Therapy for Prostate Cancer -- chapter 28 Antiangiogenic Therapy for Hematologic Malignancies -- chapter 29 Antiangiogenic Therapy for Gliomas -- chapter 30 Antiangiogenic Therapy for Kaposi’s Sarcoma -- chapter 31 Antiangiogenic Therapy for Melanoma -- chapter 32 Sunitinib and Renal Cell Carcinoma.